Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus tislelizumab for advanced or metastatic penile cancer
ChiCTR2000040095Phase 4Completed
- Sponsor
- Beijing Chaoyang Huanxing Cancer Hospital
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in penile squamous cell carcinoma (PSCC), sponsored by Beijing Chaoyang Huanxing Cancer Hospital. Primary endpoints: Measurable lesion size before treatment (Lesion B), Measurable lesion size after treatment (Lesion A) and 2 more. Started Nov 2020; status: completed.
02
Drugs
tislelizumab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2000040095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040095.